The pathogenesis of COVID-19-induced IgA nephropathy and IgA vasculitis: A systematic review

Hareem Farooq, MBBSa, Muhammad Aemaz Ur Rehman, MBBS,*, Abyaz Asmar, MBBS, Salman Asif, MBBS, Aliza Mushtaq, MBBS and Muhammad Ahmad Qureshi

Department of Medicine, Mayo Hospital, King Edward Medical University, Lahore, Pakistan

Received 17 June 2021; revised 19 August 2021; accepted 28 August 2021; Available online 28 September 2021

Abstract

Objective: IgA nephropathy (IgAN) and IgA vasculitis (IgAV) are part of a similar clinical spectrum. Both clinical conditions occur with the coronavirus disease 2019 (COVID-19). This review aims to recognize the novel association of IgAN and IgAV with COVID-19 and describe its underlying pathogenesis.

Methods: We conducted a systematic literature search and data extraction from PubMed, Cochrane, ScienceDirect, and Google Scholar following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results: Our search identified 13 cases reporting IgAV and IgAN associated with COVID-19 infection and 4 cases of IgAN following COVID-19 vaccination. The mean, mode, and median ages of patients were 23.8, 4, and 8 years, respectively. Most cases associated with COVID-19 infection were reported in males (77%). Rash and purpura (85%) were the most common clinical features, followed by gastrointestinal symptoms (62%).

* Corresponding address: Neela Gumbad, Anarkali, Lahore, Pakistan 54000, Pakistan.
E-mail: aemaz100@gmail.com (M. Aemaz Ur Rehman)
Peer review under responsibility of Taibah University.

Production and hosting by Elsevier

Taibah University
Journal of Taibah University Medical Sciences
www.sciencedirect.com

1658-3612 © 2021 The Authors.
Production and hosting by Elsevier Ltd on behalf of Taibah University. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). https://doi.org/10.1016/j.jtumed.2021.08.012

* Both authors (Hareem Farooq and Muhammad Aemaz Ur Rehman) contributed equally to this article. Hence, both are considered as first authors.
symptomatic cases, skin or renal biopsy and immunofluorescence confirmed the diagnosis of IgAN or IgAV. Most patients were treated with steroids and reported recovery or improvement; however, death was reported in two patients.

**Conclusion:** There is a paucity of scientific evidence on the pathogenesis of the association of IgAN and IgAV with COVID-19, which thus needs further study. Current research suggests the role of IgA-mediated immune response, evidenced by early seroconversion to IgA in COVID-19 patients and the role of IgA in immune hyperactivation as the predominant mediator of the disease process. Clinicians, especially nephrologists and paediatricians, need to recognize this association, as this disease is usually self-limited and can lead to complete recovery if prompt diagnosis and treatment are provided.

**Keywords:** COVID-19; IgA Nephropathy; IgA Vasculitis; Immune hyperactivation; Seroconversion

© 2021 The Authors.
Production and hosting by Elsevier Ltd on behalf of Taibah University. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

### Introduction

With an incidence of 3–16% in healthy individuals, IgA nephropathy (or Berger’s disease) is the most common type of glomerulonephritis across the world.\(^1\)\(\textsuperscript{-5}\) It can be seen more frequently in the second and third decades of life, and the name originates from predominant IgA immune complex deposition in the glomerular mesangium on biopsy.\(^6\) The classic clinical picture is a child or young adult who develops episode(s) of gross or microscopic haematuria resulting from an upper respiratory tract infection.\(^2\) It may cause acute renal failure characterized by ankle oedema, facial puffiness, and hypertension. The clinical features are more in line with a nephritic type syndrome, while a nephrotic type rarely occurs in IgA nephropathy.\(^1\) Closely related to IgA nephropathy is another clinical entity called Henoch Schonlein Purpura (HSP), an IgA-mediated systemic small-vessel vasculitis that, in addition to the kidneys, affects the skin (purpura), joints (arthritis), gut (melena, abdominal pain), etc.\(^3,5\) The definitive diagnosis of both can only be made on biopsy and the main distinction between the two is the extra-renal involvement seen in HSP.\(^2\) Many researchers have upheld the view that both diseases are part of the same spectrum and their underlying pathology is almost identical.\(^10,11\)

In December 2019, a new viral disease known as COVID-19 was identified. As of May 26, 2021, the World Health Organisation has confirmed more than 167 million cases of this infection on its official website. Although the virus is causing many unknown systemic effects in the human body, it has also been identified as an etiological factor or trigger for some well-recognised clinical entities. Among these conditions, IgA nephropathy and IgA vasculitis (or HSP) are being increasingly described in conjunction with COVID-19. Recent studies have highlighted the role of serum IgA in immune hyperactivation and early seroconversion to IgA in COVID-19 patients.\(^12,13\) This evidence may serve as the most plausible explanation for the rise in reported cases of these IgA-mediated diseases, but a comprehensive review that explores this link has not yet been published. Not only does this systematic review serve to elucidate this research question, but it also intends to review other possible pathogenic mechanisms at play. A detailed account of underlying pathogenesis can guide treatment, as well as expand the scientific understanding of researchers at large. A compilation of all such cases will alert practising physicians about rare manifestations of SARS-CoV-2 infection and enhance their knowledge regarding the likely clinical presentation. Timely diagnosis and prompt treatment will improve morbidity and mortality, and ultimately enhance patient care. Given the recent origination of this virus and the paucity of literature on the topic under discussion, a systematic review of cases remains the only reliable medical evidence for researchers and physicians. It also lays a foundation for future researchers as they expand our understanding of this novel clinical association.

### Materials and Methods

**Search strategy**

A systematic literature search was conducted (May 29, 2021) on the following four databases: PubMed/MEDLINE, Cochrane, ScienceDirect, and Google Scholar. The search string consisted of a combination of keywords and Mesh terms such as: ‘COVID-19’[MeSH], ‘Covid’\(^\textsuperscript{*}\), ‘SARS-CoV-2’, ‘purpura, schoenleinhenoch’[MeSH], ‘glomerulonephritis, iga’[MeSH], ‘IgA vasculitis’, ‘IgA nephropathy’, ‘Berger’ etc. The complete search string used in each database is provided in the Supplementary files. In order to capture all the available literature, no filter in terms of time, study design, language, country of publication, etc. was used.

**Study selection and data extraction**

The articles were searched and screened according to the PRISMA flowchart (Figure 1). The records identified through the preliminary search were downloaded into Mendeley and duplicates were removed. Two independent reviewers, HF and MAR, performed the screening and concluded that only case reports and letters to the editor have been published on this topic. In total, 16 articles were shortlisted; 13 articles discussed cases of COVID-19-infection-associated IgAN/IgAV, while another 3 reported COVID-19-vaccine-triggered IgAN. These articles’ bibliographies were sieved to identify any missed cases. All the selected articles were reviewed thoroughly and essential data (e.g. demographics, clinical course, laboratory investigations, and outcome) were extracted and summarised in the form of three tables. Continuous variables are

---

**Table 1:**

| Diagnosis           | Number of Cases | Details |
|---------------------|-----------------|---------|
| IgA Nephropathy     | 12              |         |
| IgA Vasculitis      | 3               |         |
| HSP                 | 20              |         |

**Table 2:**

| Clinical Features   | Number of Cases | Details |
|---------------------|-----------------|---------|
| Haematuria          | 15              |         |
| Hypertension        | 12              |         |
| Oedema              | 20              |         |

**Table 3:**

| Treatment Method    | Number of Cases | Details |
|---------------------|-----------------|---------|
| Steroids            | 16              |         |
| Plasmapheresis      | 2               |         |
| Other Medications   | 10              |         |

---

1. H. Farooq et al. (2021). The Authors. Production and hosting by Elsevier Ltd on behalf of Taibah University. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

---
presented as mean, mode, and median, whereas the categorical variables are presented as absolute values and percentages. Microsoft Excel was used for data extraction as well as the calculation of these variables. The references were added through Zotero.

Quality assessment

The quality of case reports was assessed by Joanna Briggs Institute Critical Appraisal Tool. Three reviewers (SA, AM, MAQ) first scored each article independently and then awarded a consensus score to each. The score report is provided in the Supplementary files.

Results

Our search of the four databases identified 2316 articles; 159 were excluded due to duplication and 2140 were removed due to irrelevance to the subject. One article, even though initially considered due to a similar clinical picture to IgAV, was eventually removed as it ruled out IgAV and concluded with a different diagnosis after histological investigations. Finally, 16 articles were selected for inclusion: 13 articles,15–27 including 9 case reports16–22,26,27 and 4 letters to the editor,15,23–25 reported cases of IgAN and IgAV following COVID-19 infection. The data of these 13 cases are summarized in the form of two tables (Tables 1 and 2), one focusing on notable clinical findings and outcomes, the other on major laboratory investigations. Additionally, three articles28–30 describing a total of four patients with COVID-19-vaccination-triggered IgAN were found. These are also described in our article to broaden the scope of this review, as the underlying pathogenic mechanisms might be closely linked to COVID-19-infection-related IgAN/IgAV (Table 3).

For the 13 patients for whom COVID-19-infection-related IgAV/IgAN, was described, the mean age was 23.8 years (range 1–78 years), with the mode and median being 4 and 8 years, respectively. Approximately half the patients belonged to the paediatric population (below 18; n = 7, 54%), while six patients were adults (above 18; n = 6, 46%). Ten cases were reported in males (77%) and three in females (23%). Ten patients had ongoing COVID-19 infection upon presentation (77%); six patients (46%) were clinically symptomatic whereas four (31%) were asymptomatic with a positive PCR result. In the remaining three patients (23%), COVID-19 infection had resolved before the onset of IgAN/IgAV. This was suggested by either history, previously positive RT-PCR, or now-positive antibody response (IgM/IgG).

The most commonly reported symptoms of IgAV/IgAN were rash/purpura (n = 11, 85%), gastrointestinal symptoms, like abdominal pain, melena/haematochezia, haematemesis etc. (n = 8, 62%), joint problems/pain (n = 7, 54%) and oedema (n = 4, 31%). Urinalysis reported proteinuria and haematuria in six (46%) and four (31%) patients, respectively. The cornerstone of definitive diagnosis in all

---

From: Mohr D, Libeskind J, Tekute J, Altman DG. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed.1000097

Figure 1: PRISMA flow diagram.
| Serial No. | Author, Year Country | Age (years), Gender | Notable Medical History | COVID-19 Status | Time between IgAN/IgAV symptoms & COVID-19 | Clinical Features (COVID-19) | Clinical Features (Renal) | Clinical Features (Extra-Renal) | Treatment | Outcome | Follow Up |
|-----------|----------------------|---------------------|-------------------------|-----------------|------------------------------------------|-----------------------------|--------------------------|-------------------------------|-----------|---------|-----------|
| 1         | Matthieu Allez et al. 2020 | 24, M               | Crohn disease           | Ongoing, asymptomatic | Both diagnosed simultaneously | –                          | –                       | Skin rash, arthralgia, periarticular swelling, abdominal pain | Steroids, LMWH | Discharged on day 7 on oral steroids & enoxaparin | –         |
| 2         | Andrea S Suso et al. 2020 | 78, M               | Alcohol consumption, HTN, dyslipidemia, aortic stenosis, bladder cancer | Past, resolved | 21 days after COVID-19 | –                          | Lower limbs pitting edema, HTN | Wrist arthritis, lower limb purpura | Steroids, rituximab | Serum Cr, urine output & purpura improved but proteinuria & hematuria persisted | –         |
| 3         | Brett Hoskins et al. 2021 | 2, M                | None                    | Ongoing, asymptomatic | Both diagnosed simultaneously | –                          | –                       | Abdominal pain, hematochezia, nonbloious LMWH emesis with blood streaks, skin rash | Steroids, LMWH | Within 48 h of treatment, cutaneous lesions & abdominal pain improved | 1 week after discharge: complete resolution |
| 4         | Dalal Anwar AlGhoozi et al. 2020 | 4, M                | None                    | Past, resolved | 37 days after COVID-19 | –                          | Edema (Ankle) | Pruritic, maculopapular rash, ankle pain | Paracetamol | Discharged the following day, remained pain-free & able to bear weight | 1 week after discharge: rash still present, urinalysis normal |
| 5         | Nicholas L Li et al. 2020 | 30, M               | None                    | Ongoing, symptomatic | Both diagnosed simultaneously | Fever, runny nose, cough, diarrhea | Frothy urine | Nonbloody diarrhea, abdominal pain, painful purpuric rash, wrist pain | Steroids | Within next 10 days COVID-19 symptoms & rash completely resolved | 6 weeks after diagnosis: hematuria & proteinuria on dipstick, RFTs stable, Cr near normal |
| 6         | Michal Jacobi et al. 2021 | 3, M                | Hirschprung disease     | Ongoing, asymptomatic | –                          | –                          | –                       | Mildly dehydration, purpuric rash, abdominal pain, nonbloious emesis | Steroids, empiric antibiotic therapy, IV fluids, NSAIDs | Responded well to steroids & was discharged | –         |
| 7         | China 65, F            |                     |                         |                 |                           |                           |                         |                                |                       |                     |  –          |
| Author                        | Country | Age | Gender | Duration Before COVID-19 | Symptoms | Treatment | Outcomes |
|-------------------------------|---------|-----|--------|--------------------------|----------|-----------|----------|
| Yi Huang et al.²¹, 2020       |         |     |        | Ongoing, symptomatic     | Myalgia, fatigue, headache & cough, Dark colored urine, flank pain, HTN | Steroids, valsartan, oseltamivir | Patient became clinically asymptomatic 3 months later: asymptomatic, UACR mildly high, eGFR normal, urine RBC high |
| Simona Gurzu et al.²², 2020   | United Kingdom | ~1 | F | None | Symptomatic, not confirmed on PCR | Cough, chills, shortness of breath & fever | IV fluid boluses, oxygen therapy |
| Sunmeet Sandhu et al.²³, 2020 | India   | 22 | M | Ongoing, symptomatic | Fever, Edema | Abdominal pain, vomiting, joint swelling, raised symmetrical lesions on all extremities | Death |
| Laura Barbetta et al.²⁴, 2021 | Italy   | 62 | M | Ongoing, symptomatic | Dyspnea, fever | Purpuric lesions with raised papules, abdominal pain, vomiting, haematochezia, hydroxychloroquine, antibiotics, antivirals | Improvement of renal function, progressive remission of abdominal pain & purpura |
| Mahdieh Sadat Mousavi et al.²⁵, 2020 | Iran | 6 | M | HSP | Symptomatic, not confirmed on PCR | Palpable purpuric maculopapular rash, arthritis, abdominal pain, melena | Steroids, ibuprofen, antibiotics, Bisoprolol, telmisartan, statin |
| Mayron D. Nakandakari et al.²⁶, 2020 | Peru | 4 | F | Past, resolved | Dry cough, rhinorrhea, fever | Maculopapular lesions, painful feet, hematemesis, abdominal pain | Death |
| Sarah Falou et al.²⁷, 2021    | Lebanon | 8 | M | Ongoing, asymptomatic | Purpura, ankle pain | IV hydration, NSAIDs, paracetamol | Discharged on 5th day, rash & ankle pain resolved |

Abbreviations: M Male, F Female, GFR Glomerular Filtration Rate, Cr Creatinine, HSP Henoch Schonlein Purpura, HTN hypertension, RFTs Renal Function Tests, LFTs Liver Function Tests, UACR Urine Albumin to Creatinine Ratio, IV Intravenous, LMWH Low Molecular Weight Heparin, NSAIDs Nonsteroidal Anti-inflammatory Drugs, CPAP Continuous Positive Airway Pressure (−) data not reported.
| Serial No | Author, Year | COVID-19 Diagnosis | Relevant Investigations | Renal Function Tests | Urinalysis | Serum IgA levels (g/L) | Renal Biopsy | Renal Electron Microscopy | Skin Biopsy | Immunofluorescence | GI/Abdominal Investigations |
|-----------|--------------|---------------------|-------------------------|---------------------|------------|------------------------|--------------|------------------------|-------------|------------------------|-----------------------------|
| 1         | Matthieu Allez et al.15, 2020 | RT-PCR | CRP raised, D-dimer raised, Fibrinogen raised, C4 raised | Cr normal, Normal | Normal | High (5.3) | — | — | Perivascular & vessel wall infiltration by neutrophils & lymphocytes, leukocytoclasia | Skin biopsy: IgA & C3 positive | CT: circumferential bowel wall thickening & hyperenhancement of the inner mucosa & submucosal edema |
| 2         | Andrea S Suso et al.16, 2020 | IgM/IgG Antibody | Albumin decreased, C3 & C4 normal | Cr high, Proteinuria, hematuria with dysmorphic RBCs | Normal | Glomerular sclerosis, segmental mesangial expansion with hypercellularity, epithelial crescents, obliterated glomerular capillary lumens | Electrodense mesangial deposits with podocytes showing extensive pedicular effacement | — | Cutaneous vasculitis | Renal biopsy: IgA granular deposits |
| 3         | Brett Hoskins et al.17, 2021 | RT-PCR | Albumin decreased, CRP raised, ESR raised | Cr low, Normal | Normal | — | — | — | Superficial perivascular inflammation with neutrophils | Skin biopsy: IgA positive | EGD: edema, erythema, superficial erosions in the stomach & duodenum |
| 4         | Dalal Anwar AlGhoozi et al.18, 2020 | RT-PCR | CRP normal, ESR normal | Normal | Normal | Normal | — | — | — | — | — |
| 5         | Nicholas L Li et al.19, 2020 | RT-PCR | CRP raised, D-dimer raised, C3 & C4 normal | Normal | Proteinuria, hematuria | Normal | Focally crescentic & segmentally necrotizing IgAN with focal endocapillary hypercellularity | Mesangial & subendothelial immune-type deposits | Neutrophil rich small-vessel vasculitis | Skin biopsy: IgA, IgG, — IgM, C3 negative | Renal biopsy: IgA positive |
| 6         | Michal Jacobi et al.20, 2021 | RT-PCR | Thrombocytosis, Hb decreased, Metabolic acidosis | Normal | Normal | — | — | — | — | — | US: increased bowel wall thickness on the left side |
| 7         | Yi Huang et al.21, 2020 | RT-PCR | CRP raised, eGFR low, Proteinuria | High (4.71) | Proteinuria | Glomerular sclerosis, fibrocellular crescent, interstitial fibrosis associated with | Mesangial immune deposits | — | Renal biopsy: 2+ granular mesangial staining for IgA, C3, kappa & lambda light chains | — | — | — |
| Case | Authors | Diagnosis | Clinical Findings | Pathological Findings |
|------|---------|-----------|------------------|----------------------|
| 8    | Simona Gurzu et al. 2020 | Clinical diagnosis | Hb decreased, RBC decreased, Hct decreased, CRP raised, Urea high, Leukocytouria, mononuclear inflammation | Enlarged mesangium with IgA-positive cells, proliferated WT1-positive podocytes, interstitial nephritis with mononuclear cells |
| 9    | Sunmeet Sandhu et al. 2020 | RT-PCR CRP normal | Hb normal, Cr low, Proteinuria, Leukocytoclastic, Skin biopsy: IgA positive, US: normal | Enlarged mesangium with IgA-positive cells, proliferated WT1-positive podocytes, interstitial nephritis with mononuclear cells |
| 10   | Laura Barbetta et al. 2021 | RT-PCR | Proteinuria, hematuria, glycosuria, hyaline cast | Perivascular & interstitial lymphocytic infiltrate, extravasated RBCs, ectasic capillaries, endothelial cells with signs of swelling without atypia |
| 11   | Mahdieh Sadat Mousavi et al. 2020 | Clinical diagnosis | Proteinuria, hematuria | Skin biopsy: IgA vascular deposits, US: mural thickening of distal ileum, decreased peristalsis, US: thickened cecum wall with an inflammatory appearance |
| 12   | Mayron D. Nakandakari et al. 2020 | IgM/IgG Antibody | Thrombocytosis, aPTT prolonged, Hb, total proteins Cr low & albumin decreased, Urea, skin biopsy | Skin biopsy: IgA vascular deposits, US: enteritis with oedema of the last 40 cm of ileal intestinal tract |
| 13   | Sarah Falou et al. 2021 | RT-PCR CRP normal, platelets normal | Cr normal Normal | |

Abbreviations: RT-PCR Reverse Transcriptase-Polymerase Chain Reaction, CRP C-Reactive Protein, ESR Erythrocyte Sedimentation Rate, Hb Hemoglobin, Hct Hematocrit, Cr Creatinine, RBCs Red Blood Cells, IgAN IgA Nephropathy, US Ultrasound, EGD Esophagogastroduodenoscopy, aPTT Activated Partial Thromboplastin Time, (-) data not reported.
Table 3: Demographics, past history, presentation and investigations of COVID-19 vaccine triggered IgA Nephropathy.

| Serial No | Author, Year | Country Reported | Age (years), Gender (M/F) | Notable Medical History | Time between 2nd dose & hematuria | Vaccine administered | Clinical Features | Relevant Serum Investigations | Urinalysis | Renal Histology & Immunofluorescence | Comments |
|-----------|--------------|------------------|---------------------------|-------------------------|----------------------------------|----------------------|-------------------|-----------------------------|------------|--------------------------------------|----------|
| 1         | Hui Zhuan Tan et al., 2021 | Singapore | 41, F | Gestational Diabetes | 1 day | Pfizer | Hematuria, headache, generalised myalgia | Cr high, IgA high, C3 low | RBCs, protein to creatinine ratio high | Glomerular IgA staining, focal proliferative glomerulonephritis, mild tubular atrophy & inflammation, mild vessel hyalinosis | Preexisting undiagnosed IgA nephropathy might have been unmasked due to vaccination |
| 2         | Lavinia Negrea et al., 2021 | USA | 38, F | IgAN | Several hours | Moderna | Body aches, headache, fever, fatigue, chills, gross hematuria | Cr normal | RBCs | Exacerbation of preexisting IgAN after vaccination, progressive increase in proteinuria with each dose of vaccine |
| 3         | Lavinia Negrea et al., 2021 | USA | 38, F | IgAN | Several hours | Moderna | Body aches, headache, fever, fatigue, chills, gross hematuria | Cr normal | RBCs | Exacerbation of preexisting IgAN after vaccination, progressive increase in proteinuria with each dose of vaccine |
| 4         | Shab E Gul Rahim et al., 2021 | USA | 52, F | IgAN | 1 day | Pfizer | Gross hematuria, fever, myalgias, body aches, lower back pain | Cr normal | RBCs, protein to creatinine ratio high | Exacerbation of preexisting IgAN after 2nd dose of vaccine |

Abbreviations: M Male, F Female, Cr Creatinine, IgAN IgA Nephropathy, RBCs Red Blood Cells, USA United States of America (–) data not reported.
patients was either renal or skin biopsy; abnormal renal biopsy was seen in five cases (39%), whereas skin biopsy abnormalities were reported in six patients (46%). Seven samples (54%) demonstrated positive IgA immunofluorescence: two from kidneys, four from the skin, and one from both the kidneys and the skin.

Immunosuppressants and supportive therapy were the mainstays of treatment. Most (n = 9, 69%) patients were treated with steroids, while some patients were also administered antihypertensives, analgesics, and antimicrobials. Among the 12 cases that reported proper outcome/follow-up, 10 (83%) improved significantly with the treatment, whereas death was reported in 2 patients (17%). Both cases of death were reported in the paediatric age group, one in an infant and the other in a child of six years.

Three articles reporting four cases of IgA nephropathy following COVID-19 vaccination have also been described in the literature. All patients were adult females, and the vaccines responsible for this presentation were Moderna and Pfizer (two cases each). Three of these cases occurred as flare-ups in known cases of IgA nephropathy; however, one occurred in a patient who had no previous history of IgAN. The details are summarised in Table 3.

**Discussion**

With COVID-19 cases increasing globally, new manifestations of this virus are unfolding before the medical community. This virus of Chinese origin reportedly affects almost every human organ, thus causing cutaneous, renal, cardiac, psychological, neurological, and even vascular problems. Though various types of vasculitides and kidney injury have been well reported with COVID-19, little is known about IgA-mediated systemic vasculitis (Henoch Schönlein Purpura) and nephropathy. With increasing evidence of IgA’s role in COVID-19 immune response, cases of IgA immune complex deposition diseases, like IgA vasculitis and IgA nephropathy, are also rising. There has been a debate among the medical fraternity on the description of IgAV and IgAN as distinct clinical entities, and various specialists consider them part of the same clinical spectrum.

IgA vasculitis characteristically presents with a tetrad of symptoms, including palpable purpura (in absence of concurrent thrombocytopenia or coagulation disorder), arthralgia/joint pain, abdominal discomfort/pain, and renal involvement. On the other hand, IgA nephropathy is predominantly a renal disease. The criteria devised by the European League Against Rheumatism (EULAR), Paediatric Rheumatology International Trials Organization (PRINTO), and Paediatric Rheumatology European Society (PRES) are usually employed in the clinical diagnosis of IgAV in children but have limited utility in adult patients. In fact, in order to allow for diagnosis, the presence of purpura along with any of the four features (namely abdominal pain, arthritis, renal disease, or IgA-mediated vasculitis/glomerulonephritis) is required. Although these criteria were not described in all cases per se, the clinical approach used was well in line with them. Rash/purpura was the most common presenting complaint in the cases fulfilling the inclusion criteria of our study, which is consistent with larger clinical studies describing rash as the most common finding in IgAV. Well in line with the literature, most cases of IgAN/IgAV associated with COVID-19 were seen in male children or young adults; however, three cases in old age have been described with SARS-CoV-2, which is rare but also has been reported previously.

With regards to pathogenesis, the most widely accepted is the ‘multi-hit hypothesis’. Raised levels of Galactose deficient IgA1 (Gd-IgA1) are crucial for the development of both IgA nephropathy and HSP nephritis. Generation of IgG autoantibodies can be seen targeting these IgA1 immunoglobulins, which leads to the immune complex formation and an inflammatory process; however, the role of the same immune complexes for extrarenal components of HSP is not well established. For vasculitic/extrarenal components of HSP, a multi-hit model involving IgA1-AECA (anti-endothelial cell antibody) is accepted. The exact role of COVID-19 in the development of these IgA-related diseases is still being explored, although several possibilities exist. Mucosal infections are believed to enhance IL-6 production that stimulates poor glycosylation/galactosylation of IgA1, thus forming Gd-IgA1 and contributing towards the disease process of IgA vasculitis nephritis (IgAVN) and IgA nephropathy (IgAN). COVID-19, being a mucosal infection as well, might cause IgAVN and IgAN through this pathway. Studies have revealed that bone marrow is the source of increased IgA1-producing B lymphocytes in patients with IgA nephropathy. The cytokines released in COVID-19 (such as IL-1, IL-6, and TNF) can also potentially lead to the proliferation and maturation of these IgA1-producing B cells, hence leading to IgAN.

Research is being carried out to document the diagnostic significance of detecting humoral response against SARS-CoV2 infection and IgA antibodies are emerging as pivotal markers. Early seropositivity of IgA, emerging two days after initial symptomatology in COVID-19 patients, is being reported in comparison to five days for IgG and IgM. This might be one of the factors responsible for the formation of immune complexes involving IgA. A previous systematic review exploring the link of COVID-19 with autoimmune diseases has been conducted, suggesting various mechanisms leading to deleterious effects. The complex genome of this virus and its tendency to mimic molecular machinery enhances its ability to cause autoimmune diseases, which might be a possible link of this phenomenon with IgAN and IgAV occurring alongside SARS-CoV2 infection.

Moreover, we know that Henoch Schönlein Purpura can be triggered by a variety of other bacterial and viral infections including coxsackievirus, parvovirus, adenovirus, hepatitis A/B, Staphylococcus aureus, and group A streptococcus, thus further strengthening our idea of its ominous relationship with coronavirus. Evidence also suggests that COVID-19 is capable of inducing endothelial injury as a result of viral components directly affecting endothelial cells via ACE2 receptors, as well as indirectly through inflammation occurring due to defence mechanisms of the host.

COVID-19 infection has also been observed to exacerbate pre-existing IgA nephropathy, as per one of the case reports included in our study, but the underlying mechanism is debatable. Interestingly, cases of IgA nephropathy also appeared following COVID-19 vaccination in a few individuals. Three cases have described flare-ups or worsening of already existing IgA nephropathy following SARS-
CoV-2 vaccination, while one case reported appearance of IgAN in a previously healthy patient (although the authors suspected that this patient might have had undiagnosed IgAN). Excessive production of IgA1 monomers in IgAN patients in response to influenza vaccine has been described previously; hence, the possibility that a similar process occurs after COVID-19 vaccination exists. Some scientists are still looking for a plausible explanation regarding the development of IgAN nephropathy despite the non-mucosal injection of the vaccine. It has been postulated that in susceptible patients with pre-existing under-galactosylated IgA1 antibodies, the vaccine triggers the production of anti-glycan antibodies that combine with the former and lead to IgAN.

The significance of steroids in treating IgAV and IgAN has been interrogated by various scientists and is said to be controversial. In our study, most of the patients suffering from COVID-related IgAN and IgAV were subjected to treatment with steroids along with other options available, particularly antibiotics and antihypertensives. As per our results, a favourable outcome was observed in most cases. This is consistent with the understanding that IgAV is a self-limited disease, but it is hard to conclude whether this favourable outcome was due to the self-limiting nature of the disease itself or the efficacy of steroids in treating IgAV.

Based on the evaluation and discussion of the few case reports published so far, the authors would like to emphasize that there are chances of IgAN and IgAV being reported in connection with COVID-19 in the future. Various case reports and reviews have described other forms of vasculitis in COVID-19 too, most commonly Kawasaki disease and some types of leukocytoclastic vasculitis. The herculean task of managing this virus is already imposing a burden on healthcare systems worldwide, and associated conditions like IgAV and IgAN can make it all the more challenging. We believe that physicians should take this association into account when examining patients with ongoing or resolved COVID-19 infection who present with symptoms depicting renal pathology, especially patients with a history of hypertension or kidney disease. Timely inspection and treatment would pave the way to improved prognosis of such patients. Furthermore, a focus on more clinical research in this area is needed in order to better understand its incidence and underlying mechanism, as well as providing reliable information in this regard.

The authors would like to acknowledge some limitations as well. We realize that the sample size in our study is small owing to the lack of published articles related to our research question. Since most of the relevant literature includes case reports, it is harder to extrapolate results from the entire population. Serum IgA/Creatinine ratio was not reported in most of the cases, despite its well-known utility in diagnosing IgAN and predicting its outcome. The authors independently scored case reports using the Critical Appraisal Tool, so there is a possibility of subjectivity in quality assessment. Lastly, we suspect publication bias, as clinicians are more likely to report clinically significant, unique, and challenging cases.

**Conclusion**

IgA-mediated diseases like IgA vasculitis and IgA nephropathy are increasingly occurring in connection with COVID-19. The evidence for the role of IgA in the immune response against COVID-19 is also increasing. The enhancement of IL-6 levels as a result of a mucosal infection like SARS-CoV2 leads to aberrant glycosylation of IgA1 antibodies, forming immune complexes with IgA autoantibodies and depositing in the tissues. Flare-ups/worsening of pre-existing IgAN and new-onset IgAN have also been reported following SARS-CoV-2 vaccination. Special attention must be given by the clinicians to COVID-19 patients belonging to the paediatric age group who present characteristic features of these diseases; however, the possibility of these infections in old age must not be ignored if clinical suspicion exists. Patients may suffer from IgA vasculitis or IgA nephropathy during or even after the resolution of COVID-19 infection, and cases following vaccination have also been reported. Since the vaccination drive and the pandemic are still ongoing, physicians should take common complaints like rash, abdominal pain, and haematuria very seriously. Although most cases are self-limited, timely diagnosis and supportive treatment are still beneficial to prevent long-term consequences to the patient’s health.

**Source of funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Conflict of interest**

The authors have no conflict of interest to declare.

**Ethical approval**

The authors confirm that this review has been prepared in accordance with COPE guidelines and regulations. Given the nature of this article, IRB review was not required.

**Authors’ contributions**

HF developed the idea of the study, performed a literature search, designed the PRISMA flowchart, analysed the results using Excel, and drafted the manuscript. MAR also developed the idea of the study, performed a literature search, designed the PRISMA flowchart, and drafted the manuscript. AA performed a literature search, interpreted the data after analysing it, and drafted the manuscript. SA generated and filled the tables with data, performed data analysis, and scored case reports on critical appraisal. AM generated and filled the tables with data, interpreted the data, and scored case reports on critical appraisal. MAQ refined the article design, filled the tables with data, interpreted the data, and scored case reports on critical appraisal. All authors have critically reviewed and approved the final draft and are responsible for the content and similarity index of the manuscript.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jtumed.2021.08.012.
65. Namgoong M, Namgoong M. Management of IgA vasculitis nephritis (Henoch-Schönlein purpura nephritis) in children. *Child Kidney Dis* 2020 Apr 30; 24(1): 1–13. https://doi.org/10.3339/jkspd.2020.24.1.1.

66. Kurnia B. Henoch-Schönlein Purpura in children: the role of corticosteroids. *Open Access Maced J Med Sci* 2019 Jun 15; 7(11): 1812–1814. 10.3889/oamjms.2019.538. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614272/. PMID: 31316664, PMCID: PMC6614272.

67. Jiao F-Y. Kawasaki disease - a new manifestation of COVID-19 in children. *Zhongguo Dang Dai ErKeZaZhi Chin J Contemp Pediatr* 2020 Jul; 22(7): 677–678. https://doi.org/10.7499/jissn.1008-8830.2005117.

68. Kumar G, Pillai S, Norwick P, Bukulmez H. Leucocytoclastic vasculitis secondary to COVID-19 infection in a young child. *BMJ Case Rep CP* 2021 Apr 1; 14(4):e242192. https://doi.org/10.1136/bcr-2021-242192.

69. Gómez MC, González-Cruz C, Ferrer B, Barberá MJ. Leucocytoclastic vasculitis in a patient with COVID-19 with positive SARS-CoV-2 PCR in skin biopsy. *BMJ Case Rep CP* 2020 Oct 1; 13(10):e238039. https://doi.org/10.1136/bcr-2020-238039.

70. Gong W, Liu M, Luo D, Liu F, Yin L, Li Y, et al. High serum IgA/C3 ratio better predicts a diagnosis of IgA nephropathy among primary glomerular nephropathy patients with proteinuria ≤ 1 g/d: an observational cross-sectional study. *BMC Nephrol* 2019 Dec; 20(1): 1–12. https://doi.org/10.1186/s12882-019-1331-0.

71. Tomino Y, Suzuki S, Imai H, Saito T, Kawamura T, Yorioka N, et al. Measurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy. *J Clin Lab Anal* 2000; 14(5): 220–223. https://doi.org/10.1002/1098-2825(200005)14:5<220::aid-jcla4>3.0.co;2-2. PMID: 11018800.

72. Zhang J, Wang C, Tang Y, Peng H, Ye ZC, Li CC, et al. Serum immunoglobulin A/C3 ratio predicts progression of immunoglobulin A nephropathy. *Nephrology* 2013 Feb; 18(2): 125–131. https://doi.org/10.1111/nep.12010.